Zusammenfassung
Stress wirkt sich durch unterschiedliche Mechanismen negativ auf den Verlauf einer chronisch-entzündlichen Darmerkrankung aus. Zu den wichtigen Mechanismen gehören u. a. eine verstärkte Freisetzung proentzündlicher Zytokine, Darmdysbiose, erhöhte Permeabilität der Darmbarriere, verstärkte Freisetzung von CRF (corticotropin-releasing factor) im Gehirn, Aktivierung der Mastzellen in der Darmschleimhaut und unzureichende zentrale Schmerzverarbeitung mit den Folgen Angst und Depression. All diese Faktoren können die entzündliche Reaktion am Darm verstärken und zum akuten Schub führen. Aus diesem Grund ist ein entsprechendes Stress-Management von außerordentlich wichtiger Bedeutung für den Therapieerfolg.
Different mechanisms have a negative impact on the course of inflammatory bowel disease. Important mechanisms include amongst others an increased release of pro-inflammatory cytokines, intestinal dysbiosis, increased permeability of the intestinal barrier, increased release of corticotropin-releasing factor (CRF) in the brain, activation of mast cells in the intestinal mucosa and inadequate central pain processing with the consequences of anxiety and depression. All of these factors can increase the inflammatory response in the intestine and lead to acute flare-ups. For this reason, appropriate stress management is extremely important for the success of therapy.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Elsenbruch S, Enck P. The stress concept in gastroenterology: from Selye to today. F1000Research 2017; 6(F1000 Faculty Rev): 2149.
Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol Metab 1946; 6: 117–230.
Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol 2011; 62 (6): 591–599.
Audet MC. Stress-induced disturbances along the gut microbiota-immune-brain axis and implications for mental health: Does sex matter? Front Neuroendocrinol 2019; 54: 100772.
Hood MM, Jedel S. Mindfulness-based interventions in inflammatory bowel disease. Gastroenterol Clin North Am 2017; 46 (4): 859–874.
Rubin DT, Siegel CA, Kane SV, et al. Impact of ulcerative colitis from patients’ and physicians’ perspectives: results from the UC: NORMAL survey. Inflamm Bowel Dis 2009; 15 (4): 581–588.
Melinder C, Hiyoshi A, Fall K, Halfvarson J, Montgomery S. Stress resilience and the risk of inflammatory bowel disease: a cohort study of men living in Sweden. BMJ Open 2017; 7 (1): e014315.
Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012; 107 (10): 1474–1482.
Labanski A, Langhorst J, Engler H, Elsenbruch S. Stress and the brain-gut axis in functional and chronic-inflammatory gastrointestinal diseases: A transdisciplinary challenge. Psychoneuroendocrinology 2020; 111: 104501.
Konturek P, Konturek K, Zopf Y, Harsch IA. Intestinal microbiota — a vital “organ” with manifold functions. MMW Fortschr Med 2020; 162 (Suppl 4): 9–14.
Gao X, Cao Q, Cheng Y, et al. Chronic stress promotes colitis by disturbing the gut microbiota and triggering immune system response. Proc Natl Acad Sci USA 2018; 115 (13): E2960–E2969.
Konturek PC, Zopf Y, Dieterich W, Wirtz S, Neurath MF, Brzozowski T. P109 Rifaximin and Saccharomyces boulardii increase stress resilience in TNBS-induced colitis. Journal of Crohn’s and Colitis, Volume 12, Issue supplement_1, 1 February 2018, Page S148.
Humbel F, Rieder JH, Franc Y, et al; Swiss IBD Cohort Study Group. Association of alterations in intestinal microbiota with impaired psychological function in patients with inflammatory bowel diseases in remission. Clin Gastroenterol Hepatol 2019; pii: S1542-3565(19)31028-6.
van de Wouw M, Boehme M, Lyte JM, et al. Short-chain fatty acids: microbial metabolites that alleviate stress- induced brain-gut axis alterations. J Physiol 2018; 596 (20): 4923–4944.
Lewis K, Marrie RA, Bernstein CN, et al; CIHR Team in Defining the Burden and Managing the Effects of Immune-Mediated Inflammatory Disease. The prevalence and risk factors of undiagnosed depression and anxiety disorders among patients with inflammatory bowel disease. Inflamm Bowel Dis 2019; 25 (10): 1674–1680.
Navabi S, Gorrepati VS, Yadav S, et al. Influences and impact of anxiety and depression in the setting of inflammatory bowel disease. Inflamm Bowel Dis 2018; 24 (11): 2303–2308.
Filipovic BR, Filipovic BF. Psychiatric comorbidity in the treatment of patients with inflammatory bowel disease. World J Gastroenterol 2014; 20 (13): 3552–3563.
Zhang Y, Pi B, Xu X, et al. Sleep characteristics and influencing factors of sleep quality in patients with inflammatory bowel disease — peripheral arthritis. Front Med (Lausanne) 2020; 6: 190.
Ballou S, Alhassan E, Hon E, et al. Sleep disturbances are commonly reported among patients presenting to a gastroenterology clinic. Dig Dis Sci 2018; 63 (11): 2983–2991.
Sobolewska-Wlodarczyk A, Wlodarczyk M, Zielinska A, et al. Circadian rhythm abnormalities in patients with inflammatory bowel disease — association with adipokine profile. Scand J Gastroenterol 2020; 55(3): 294–300.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of a supplement not sponsored by the industry.
Interessenkonflikt
Der Autor und die beiden Autorinnen erklären, dass kein Interessenkonflikt vorliegt.
Rights and permissions
About this article
Cite this article
Konturek, P.C., Konturek, K. & Zopf, Y. Stress und chronisch-entzündliche Darmerkrankungen. MMW - Fortschritte der Medizin 162 (Suppl 5), 3–6 (2020). https://doi.org/10.1007/s15006-020-0657-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15006-020-0657-7